Expert Opinion on Investigational Drugs

Article	Citations
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	106
Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development	80
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	77
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?	75
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials	74
Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia	71
Theranostic strategies in sarcoma: preliminary clinical evidence	62
Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development	61
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	56
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	53
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases	53
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	51
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	44
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	43
Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials	41
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	41
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials	37
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	37
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	35
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	33
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	32
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential	31
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	27
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	27
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	26

CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	26
Investigational drugs for the treatment of dysmenorrhea	26
Emerging treatments for chronic urticaria	22
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	22
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	22
Ewing sarcoma: investigational mono- and combination therapies in clinical trials	21
Potassium channel modulators and schizophrenia: an overview of investigational drugs	21
Recent developments in adjunct therapies for type 1 diabetes	21
Investigational drugs for immune thrombocytopenia	21
IgA nephropathy: an overview of drug treatments in clinical trials	20
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia	20
Current options and investigational drugs for the treatment of eosinophilic esophagitis	19
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer	19
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials	19
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics	18
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer	17
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	17
Duchenne muscular dystrophy: promising early-stage clinical trials to watch	16
What is the progress of experimental drug development for fibromyalgia?	16
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration	15
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options	15
Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1	15
Investigational new drugs for the treatment of leishmaniasis	15
Frontotemporal dementia: from genetics to therapeutic approaches	15
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study	15
Novel systemic treatment approaches for metastatic pancreatic cancer	15
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal	14
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials	14
Current experimental and early investigational agents for cardiac fibrosis: where are we at?	14
NF1 alterations in cancers: therapeutic implications in precision medicine	14
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists	14
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer	14
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects	13
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations	13
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents	13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease	13
Assessing the clinical progress of the bispecific nanobody sonelokimab	13
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	13
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021	13
Navafenterol for chronic obstructive pulmonary disease therapy	12
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	12
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	12
Investigational drugs for the treatment of olfactory dysfunction	12
Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials	11
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	11
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)	11
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps	11
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	11
Low-dose aspirin for early COVID-19: does the early bird catch the worm?	11
Inflammation and Huntington’s disease – a neglected therapeutic target?	10

JAK inhibitors in crohn’s disease: ready to go?	10
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	10
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	10
Camrelizumab: an investigational agent for hepatocellular carcinoma	10
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	10
Immunotherapeutic strategies for treating opioid use disorder and overdose	10
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	10
Investigational new drugs for the treatment of Dravet syndrome: an update	10
JAK inhibitors for rheumatoid arthritis	10
Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials	10
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies	10
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	10
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	9
Emerging agents for the treatment and prevention of stroke: progress in clinical trials	9
Investigational anti IL-13 asthma treatments: a 2023 update	9
The impact of current investigational drugs for acne on future treatment strategies	9
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress	9
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	9
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials	9
New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine	9
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	9
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs	9
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials	9
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers	9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections	9
Assessing potential of psilocybin for depressive disorders	9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	9
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets	8
Retinal stroke: research models, targets and experimental drugs	8
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH	8
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials	8
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials	8
Islatravir: evaluation of clinical development for HIV and HBV	8
Investigational drugs for the treatment of acromegaly: new agents to transform therapy	8
Novel investigational drugs for alopecia areata and future perspectives	8
Preclinical prospects of investigational agents for hearing loss treatment	8
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-c	8
Mantle cell lymphoma: what clinical progress in the last 5 years?	8
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents	8
Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?	8
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?	8
What have we learned from past failures of investigational drugs for Alzheimer’s disease?	7
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study	7
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease	7
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	7
Psoriasis: talking points from recent clinical trials	7
Investigational drugs in early phase trials for myelofibrosis	7
Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis	7
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs	7
AXS-05: an investigational treatment for Alzheimer’s disease-associated agitation	7
Investigational drugs in early clinical development for portal hypertension	7
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma	7
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate	7
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects	7
Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies	7
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	6
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials	6
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer	6
Developments and challenges for new and emergent preparations for male hypogonadism treatment	6
Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects	6
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects	6
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	6
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	6
Psoriasis: a focus on upcoming oral formulations	6
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects	6
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	6
Correction	6
Investigational drugs for ischemic stroke: what’s in the clinical development pipeline for acute phase and prevention?	6
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	6
Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver	6
Fibroblast growth factor therapies in biliary tract cancers: current and future state	6
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	6
Retatrutide: a triple incretin receptor agonist for obesity management	6
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications	6
Experimental drugs for the prevention or treatment of sensorineural hearing loss	6
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	6
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?	5
Fezolinetant in the treatment of vasomotor symptoms associated with menopause	5
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled do	5
Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data	5

Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development	5
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline	5
First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain	5
Adenosine pathway inhibitors: novel investigational agents for the treatment of metastatic breast cancer	5
A focused report on IFN-1 targeted therapies for lupus erythematosus	5
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation	5
Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials	5
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study	5
Long COVID [post-acute sequelae of coronavirus disease 2019]: experimental drugs for cardiopulmonary complications	5
Giant cell arteritis: what is new in the preclinical and early clinical development pipeline?	5
Experimental and new investigational drugs for the treatment of uterine fibroids	5
Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action	5
Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis	5
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation	5
Investigational drugs inhibiting complement for the treatment of geographic atrophy	5
Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials	5
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics	5
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study	5
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies	5
Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation	5
Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments	5
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?	5
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome	5
Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options	4
Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure	4
Venetoclax in acute myeloid leukemia	4
Bladder cancer: shedding light on the most promising investigational drugs in clinical trials	4
From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?	4
Prospect of CAR T-cell therapy in acute myeloid leukemia	4
Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy	4
Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis	4
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment	4
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases	4
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection	4
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	4
Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit	4
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease	4
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?	4
Insulin sensitizers in 2023: lessons learned and new avenues for investigation	4
KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases	4
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?	4
Avasopasem for the treatment of radiotherapy-induced severe oral mucositis	4
Early stage clinical trials for the treatment of hemophilia A	4
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke	4
Metabolic dysfunction and insulin sensitizers in acute and chronic disease	3
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	3
The role of phosphodiesterase 9A inhibitors in heart failure	3
Investigational drugs for HIV: trends, opportunities and key players	3
Still grasping at straws: donanemab in Alzheimer’s disease	3
Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs	3
Tolerability, safety, and pharmacokinetics of GR1603 injection in healthy subjects: a randomized, double-blind, placebo-controlled single-dose escalation clinical trial	3
Investigational treatment strategies in glioblastoma: progress made and barriers to success	3
Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers	3
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	3
New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature	3
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	3
Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma	3
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	3
Atezolizumab: an investigational agent for the treatment of biliary tract cancer	3
Anti-inflammatory therapies for acute respiratory distress syndrome	3
Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what’s new?	3
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects	3
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential	3
Experimental drugs for fallopian cancer: promising agents in the clinical trials and key stumbling blocks for researchers	3
An overview of the safety and efficacy of LX-9211 in treating neuropathic pain conditions	3
Therapies in preclinical and clinical development for Angelman syndrome	3
Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies	3
Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer	3
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer	3
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?	3
Innate immunity as a target for novel therapeutics in triple negative breast cancer	3
CNM-Au8: an experimental agent for the treatment of amyotrophic lateral sclerosis (ALS)	3
Medical treatments for abdominal aortic aneurysm: an overview of clinical trials	3
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond	3
Investigational drugs in clinical trials for macular degeneration	3
Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?	3
An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension	3